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Coumarins are a large class of compounds that display a range of interesting biological 
properties, being considered privileged structures because of the ability of their 2H-chromen-2-one 
nuclei to bind to multiple pharmacological targets. We hypothesized that the linkage of a second 
pharmacophore nucleus to the 2H-chromen-2-one core, the 1,2,3-triazole moiety, would entail 
more selective and pharmacologically active coumarins. Therefore, we describe the synthesis 
of fourteen 4-methylcoumarins/1,4-substituted 1,2,3-triazole conjugates, which were predicted 
by in silico methods to inhibit acetylcholinesterase (AChE) and proved to be moderate in vitro 
inhibitors of this enzyme. Molecular docking simulations suggest that the most active of these 
compounds has a putative binding mode similar to donepezil, both occupying the peripheral anionic 
site of AChE, which is associated with the secondary noncholinergic functions of the enzyme. 
This highlights the potential of this series for further optimization in the search of new coumarins 
for the treatment of Alzheimer’s disease.
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Introduction
Coumarins are a large class of compounds that display 
a wide range of interesting biological properties such 
as anticoagulant,1 antineurodegenerative,2 antioxidant,3 
anticancer4,5 and antimicrobial activities.6 They are 
considered good examples of privileged structures, usually 
rigid, polycyclic heteroatomic systems that are capable to 
bind to multiple pharmacological targets, thus providing a 
viable starting point in the search for new drugs.7
The 2H-chromen-2-one nucleus is the structural feature 
that is responsible for the privileged pharmacological actions 
of coumarins. This planar ring system is composed by one 
aromatic ring (Figure 1, ring A), capable of establishing 
hydrophobic, π-π, CH-π and cation-π interactions, and one 
lactone ring (Figure 1, ring B), which contains two oxygen 
atoms that may interact via hydrogen bonding with a series 
of amino acid residues, such as serine, threonine, cysteine, 
asparagine, glutamine and tyrosine. The C-C double bond 
in the 2-pyrone ring (Figure 1, ring B) is also essential 
for conferring planarity to the 2H-chromen-2-one core, 
allowing charge delocalization between the carbonyl group 
and the aromatic ring.8
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Although the synthesis of privileged structures is 
certainly a helpful strategy to find new lead compounds, 
this approach may be not so advantageous from the 
clinical point of view, since the activation of multiple 
targets by these planar ring systems may also increase the 
chances of adverse reactions and drug interactions. It was 
demonstrated that there is a significant trend for reduced 
aqueous solubility and increased inhibition of CYP3A4 
for planar aromatic compounds, e.g., warfarin, being the 
inhibition of cytochrome P450 function associated with 
a higher risk of compound toxicity and severe drug-drug 
interactions.9 
Therefore, we hypothesized that the linkage of a second 
pharmacophore nucleus to the 2H-chromen-2-one core, the 
1,2,3-triazole moiety (Figure 1, ring C), would entail more 
selective and still pharmacologically active coumarins. 
Triazoles are known to interact with several biological 
targets via coordination, hydrogen bonds, hydrophobic, 
π-π, CH-π and cation-π interactions.10 Considering that the 
regioselective synthesis of 1,4-substituted 1,2,3-triazoles 
is an example of click chemistry, this can also be a good 
strategy to achieve structural diversity, thus facilitating 
structure-activity relationship (SAR) studies through the 
generation of analog libraries.11
In this context, herein we report the synthesis of fourteen 
analogues of hymecromone (7-hydroxy-4-methylcoumarin) 
in which the 7-hydroxyl group of the coumarin was used 
to connect, via an ethyl bridge, the 2H-chromen-2-one 
core to 1,4-substituted 1,2,3-triazoles with different 
substituents at position 4. These substituents were grouped 
into three different categories: (i) hydrogen bond donors 
and acceptors; (ii) aromatic/hydrophobic groups; and 
(iii) aromatic plus hydrogen bond donors/acceptors or 
aromatic plus acceptor groups (Figure 1). As predicted by 
the in silico simulations, most of these analogues proved to 
be moderate inhibitors of the acetylcholinesterase (AChE), 
thus highlighting the potential of this series for further 
optimization in the search of clinically relevant coumarins 
for the treatment of Alzheimer’s disease.
Experimental
Chemistry
All chemicals were purchased as reagent grade 
and used without further purification. Solvents were 
distilled and/or dried according to standard methods.12 
Column chromatography was performed on silica gel 60 
(0.040-0.063 mm) using dichloromethane (CH2Cl2) 
and CH2Cl2/ethyl acetate (EtOAc), 5:1 or 2:1 (v/v). 
Microwave-assisted reactions were performed on a 
CEM Discover® microwave system (Matthews, NC, 
USA). Melting points were determined on a Fisatom 431 
apparatus (São Paulo, SP, Brazil) and are uncorrected. 
Mass spectrometer (MS) spectra were recorded on Q-Tof 
micro Waters high resolution mass spectrometer (Milford, 
MA, USA), operating in electrospray ionization mode. 
Nuclear magnetic resonance (NMR) spectra were recorded 
on Bruker Avance 400 DPX (400 MHz) spectrometer 
(Billerica, MA, USA). Chemical shifts (d) are given in parts 
per million downfield from tetramethylsilane.
7-Hydroxy-4-methylchromen-2-one (3)
Resorcinol (1 g, 9.1 mmol) and ethyl acetoacetate 
(1.15 mL, 9.1 mmol) were added to a round bottom three-
necked flask containing concentrated H2SO4 (10 mL) in ice 
bath. The reaction mixture was allowed to stir overnight 
at room temperature and the total consumption of the 
reactants was confirmed by thin layer chromatography 
(TLC; CH2Cl2/EtOAc 5:1, v/v). Ice cold distilled water 
was then added to precipitate the crude product, which was 
filtered, dissolved in a 5% (v/v) aqueous solution of NaOH, 
filtered again and reprecipitated by the addition of a 10% 
(v/v) aqueous solution of H2SO4 to give 3 as a white solid.13 
Yield 67%; mp 185-186 °C; 1H NMR (300 MHz, 
DMSO-d6) d 10.53 (s, 1H), 7.59 (d, 1H, J 8.7 Hz), 6.80 
(dd, 1H, J 8.7, 2.4 Hz), 6.70 (d, 1H, J 2.4 Hz), 6.13 (d, 1H, 
Figure 1. General structure of the 4-methylcoumarins/1,4-substituted 
1,2,3-triazole conjugates. The 2H-chromen-2-one core of coumarins 
is composed of one aromatic ring (ring A) and a lactone (ring B). The 
1,2,3-triazole moiety is also depicted (ring C). The substituents at position 4 
of the triazole (R) are grouped (counterclockwise) according to the main 
predicted interactions with the pharmacological target: (i) hydrogen bond 
donors and acceptors; (ii) aromatic/hydrophobic groups; and (iii) aromatic 
plus hydrogen bond donors/acceptor or exclusively acceptor groups.
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J 1.2 Hz), 2.36 (bs, 3H); 13C NMR (75 MHz, DMSO-d6) 
d 161.15, 160.30, 154.83, 153.57, 126.64, 112.86, 112.02, 
110.25, 102.17, 18.13; HRMS (ESI) m/z calcd. for C10H8O3 
[M + H]+: 177.0552; found: 177.0553.
7-(2-Azidoethoxy)-4-methyl-2H-chromen-2-one (5)
To a solution of 3 (704 mg, 4 mmol) in CH3CN (30 mL), 
K2CO3 (3.32 g, 24 mmol) was added and the mixture was 
allowed to reflux for 15 min. 1,2-Dibromoethane (1.03 mL, 
12 mmol) was then added and the reaction mixture was 
refluxed for additional 6 h. Consumption of the reactant 
was followed by TLC (CH2Cl2) and K2CO3 was removed 
by filtration. The crude product was concentrated, dissolved 
in CH2Cl2, washed with water, brine and dried over 
anhydrous Na2SO4. The residue was purified by column 
chromatography with a hexane/ethyl acetate gradient to 
give 7-(2-bromoethoxy)-4-methyl-2H-chromen-2-one 4 as 
a white solid, which was directly used in the subsequent 
step.
To a solution of 4 (1.7 g, 6 mmol) in acetone (30 mL), 
an aqueous solution of sodium azide (12 mmol, 0.78 g in 
5 mL of H2O) was added. The mixture was refluxed for 
12 h and the reaction followed by TLC (CH2Cl2). The 
mixture was concentrated and the residue extracted with 
ethyl acetate (3 × 30 mL). The organic phase was washed 
with brine, dried over anhydrous Na2SO4 and concentrated 
to afford 5 as a white solid.14 
Yield 89%; mp 101-102 °C; 1H NMR (300 MHz, 
DMSO-d6) d 7.70 (d, 1H, J 8.9 Hz), 7.02 (d, 1H, J 2.7 Hz), 
6.98 (dd, 1H, J 8.9, 2.7 Hz), 6.23 (d, 1H, J 1.2 Hz), 4.29 (t, 
2H, J 4.8 Hz), 3.70 (t, 2H, J 4.8 Hz), 2.40 (d, 3H, J 1.2 Hz); 
13C NMR (75 MHz, DMSO-d6) d 160.97, 160.09, 154.67, 
153.39, 126.60, 113.45, 112.46, 111.37, 101.29, 67.42, 
49.38, 18.15; HRMS (ESI) m/z calcd. for C12H12N3O3 
[M + H]+: 246.0879; found: 246.0879.
General procedure for the preparation of compounds 7a-7n
Acetylene derivatives 6a-6n (0.15 mmol L−1, 
1.1 equiv) were added to a solution of compound 5 in 
dimethylformamide (DMF; 0.5-1 mol L−1, 0.1 mL) in a 
microwave flask (0.2 mL) equipped with a stirring bar. 
Sodium ascorbate (0.1 equiv) and CuSO4 (0.03 equiv) 
were added, the tube was sealed and the mixture was 
stirred for 25 s at room temperature followed by heating 
under microwave irradiation at 70 °C (18 W) in cycles of 
20 min. Consumption of the reactant was followed by TLC 
(CH2Cl2/EtOAc 2:1, v/v). The reaction mixture was 
partitioned between H2O and EtOAc, the aqueous phase 
was extracted with EtOAc (3 to 5 times depending on 
the solubility of the compound). The organic phase was 
dried over MgSO4, filtered, concentrated and the residue 
purified by column chromatography with a CH2Cl2/EtOAc 
gradient.15
7-(2-(4-(Hydroxymethyl)-1H-1,2,3-triazol-1-yl)ethoxy)-4-
methyl-2H-chromen-2-one (7a)
White solid; yield 78%; mp 164-165 °C; 1H NMR 
(300 MHz, DMSO-d6) d 8.05 (s, 1H), 7.67 (d, 1H, J 8.7 Hz), 
7.01 (d, 1H, J 2.4 Hz), 6.94 (dd, 1H, J 8.7, 2.4 Hz), 6.21 (d, 
1H, J 1.1 Hz), 5.17 (t, 1H, J 5.4 Hz), 4.78 (t, 2H, J 5.1 Hz), 
4.54-4.51 (m, 4H), 2.38 (d, 3H, J 1.1 Hz); 13C NMR 
(75 MHz, DMSO-d6) d 160.8, 160.0, 154.6, 153.3, 148.0, 
126.5, 123.1, 113.5, 112.4, 111.4, 101.4, 66.8, 55.0, 48.6, 
18.1; HRMS (ESI) m/z calcd. for C15H15N3O4 [M + H]+: 
302.1141; found: 302.1146.
7-(2-(4-(3-Methyl-1-penten-3-ol)-1H-1,2,3-triazol-1-yl)
ethoxy)-4-methyl-2H-chromen-2-one (7b)
White solid; yield 65%; mp 134 °C; 1H NMR (400 MHz, 
DMSO-d6) d 7.93 (s, 1H), 7.67 (d, 1H, J 8.8 Hz), 6.99 (d, 
1H, J 2.6 Hz), 6.93 (dd, 1H, J 8.8, 2.6 Hz), 6.22 (d, 1H, 
J 1.2 Hz), 6.14 (dd, 1H, J 17.2, 10.6 Hz), 5.41 (s, 1H), 5.16 
(dd, 1H, J 17.2, 1.8 Hz), 4.97 (dd, 1H, J 10.6, 1.8 Hz), 4.76 
(t, 2H, J 5.0 Hz), 4.53 (t, 2H, J 5.0 Hz), 2.38 (s, 3H), 1.52 
(bs, 3H); 13C NMR (100 MHz, DMSO-d6) d 160.8, 160.0, 
154.6, 153.8, 153.3, 145.0, 140.7, 126.5, 121.7, 113.5, 
112.4, 111.4, 111.1, 101.4, 69.6, 66.8, 48.6, 28.6, 18.1; 
HRMS (ESI) m/z calcd. for C18H19N3O4 [M + Na + H]+: 
365.1352; found: 365.1358. 
7-(2-(4-(4-Propan-1-ol)-1H-1,2,3-triazol-1-yl)ethoxy)-4-
methyl-2H-chromen-2-one (7c)
White solid; yield 80%; mp 149 °C; 1H NMR (400 MHz, 
DMSO-d6) d 7.92 (s, 1H), 7.67 (d, 1H, J 8.8 Hz), 6.99 (d, 
1H, J 2.4 Hz), 6.94 (dd, 1H, J 8.8, 2.4 Hz), 6.21 (d, 1H, 
J 1.2 Hz), 4.74 (t, 2H, J 4.8 Hz), 4.51 (t, 2H, J 4.8 Hz), 
3.42 (t, 2H, J 6.4 Hz), 2.63 (t, 2H, J 7.6 Hz), 2.38 (s, 3H), 
1.72 (m, 2H); 13C NMR (100 MHz, DMSO-d6) d 160.8, 
160.0, 154.6, 153.3, 146.8, 140.7, 126.5, 122.3, 113.5, 
112.4, 111.4, 101.4, 66.8, 60.0, 48.6, 32.3, 21.6, 18.1; 
HRMS (ESI) m/z calcd. for C17H19N3O4 [M + H]+: 330.1454; 
found: 330.1443.
7-(2-(4-Phenyl-1H-1,2,3-triazol-1-yl)ethoxy)-4-methyl-2H-
chromen-2-one (7d)
White solid; yield 91%; mp 180 °C; 1H NMR 
(300 MHz, DMSO-d6) d 8.66 (s, 1H), 7.85 (m, 2H), 7.67 (d, 
1H, J 8.9 Hz), 7.44 (t, 2H, J 7.2 Hz), 7.33 (t, 1H, J 7.2 Hz), 
7.04 (d, 1H, J 2.4 Hz), 6.97 (dd, 1H, J 8.9, 2.4 Hz), 6.20 (d, 
1H, J 0.9 Hz), 4.85 (t, 2H, J 5.0 Hz), 4.58 (t, 2H, J 5.0 Hz), 
2.37 (d, 3H, J 0.9 Hz); 13C NMR (75 MHz, DMSO-d6) 
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d 160.8, 160.0, 154.6, 153.3, 146.4, 130.7, 128.9, 127.8, 
126.5, 125.1, 121.9, 113.5, 112.4, 111.4, 101.5, 66.7, 49.0, 
18.1; HRMS (ESI) m/z calcd. for C20H17N3O3 [M + H]+: 
348.1348; found: 348.1365.
7-(2-(4-(2-(Trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-yl)
ethoxy)-4-methyl-2H-chromen-2-one (7e)
White solid; yield 85%; mp 157 °C; 1H NMR (300 MHz, 
DMSO-d6) d 8.40 (d, 1H, J 0.9 Hz), 7.87-7.66 (m, 6H), 7.01 
(d, 1H, J 2.4 Hz), 6.93 (dd, 1H, J 8.7, 2.4 Hz), 6.21 (d, 1H, 
J 1.2 Hz), 4.91 (t, 2H, J 4.8 Hz), 4.59 (t, 2H, J 4.8 Hz), 
2.38 (d, 3H, J 1.2 Hz); 13C NMR (75 MHz, DMSO-d6) 
d 160.8, 160.0, 154.6, 153.3, 143.2, 132.6, 131.7, 129.5, 
128.8, 126.5, 126.3, 126.2, 124.6, 122.1, 113.5, 112.4, 
111.4, 101.4, 66.7, 48.9, 18.1; HRMS (ESI) m/z calcd. for 
C21H16F3N3O3 [M + H]+: 416.1222; found: 416.1234.
7-(2-(4-(Naphthalen-1-yl)-1H-1,2,3-triazol-1-yl)ethoxy)-4-
methyl-2H-chromen-2-one (7f)
Dark yellow liquid; yield 59%; 1H NMR (400 MHz, 
CDCl3) d 8.33-8.31 (m, 1H), 8.03 (s, 1H), 7.88-7.86 (m, 
2H), 7.70 (d, 1H, J 6.8 Hz), 7.51-7.27 (m, 4H), 6.83-6.80 
(m, 2H), 6.12 (s, 1H), 4.92 (t, 2H, J 4.6 Hz), 4.50 (t, 2H, 
J 4.6 Hz), 2.34 (s, 3H); 13C NMR (100 MHz, CDCl3) d 161.0, 
160.6, 155.0, 152.4, 146.9, 133.8, 131.0, 129.0, 128.4, 127.7, 
127.2, 126.6, 126.0, 125.8, 125.3, 125.2, 123.8, 114.3, 112.4, 
112.0, 101.7, 66.7, 49.5, 18.6; HRMS (ESI) m/z calcd. for 
C24H19N3O3 [M + H]+: 398.1505; found: 398.1505.
7-(2-(4-Phenethyl-1H-1,2,3-triazol-1-yl)ethyloxy)-4-methyl-
2H-chromen-2-one (7g)
White solid; yield 84%; mp 135 °C; 1H NMR (400 MHz, 
DMSO-d6) d 7.89 (s, 1H), 7.67 (d, 1H, J 8.8 Hz), 7.26-7.15 
(m, 5H), 6.98 (d, 1H, J 2.4 Hz), 6.92 (dd, 1H, J 8.8, 2.4 Hz), 
6.22 (s, 1H), 4.73 (t, 2H, J 5.0 Hz), 4.49 (t, 2H, J 5.0 Hz), 
2.91 (bs, 4H), 2.39 (s, 3H); 13C NMR (100 MHz, DMSO-d6) 
d 160.8, 160.0, 154.6, 153.3, 141.1, 140.7, 128.3, 128.2, 
126.5, 125.8, 122.6, 113.5, 112.4, 111.4, 101.4, 66.8, 48.6, 
34.8, 26.9, 18.1; HRMS (ESI) m/z calcd. for C22H21N3O3 
[M + H]+: 376.1661; found: 376.1668;
7-(2-(4-(2-(Hydroxymethyl)phenyl)-1H-1,2,3-triazol-1-yl)
ethoxy)-4-methyl-2H-chromen-2-one (7h)
White solid; yield 80%; mp 168-169 °C; 1H NMR 
(300 MHz, DMSO-d6) d 8.51 (s, 1H), 7.76-7.73 (m, 1H), 
7.68 (d, 1H, J 8.8 Hz), 7.59-7.56 (m, 1H), 7.37-7.35 (m, 
2H), 7.04 (d, 1H, J 2.4 Hz), 6.96 (dd, 1H, J 8.8, 2.4 Hz), 6.21 
(s, 1H), 4.88 (t, 2H, J 5.0 Hz), 4.61-4.57 (m, 4H), 2.38 (s, 
3H); 13C NMR (75 MHz, DMSO-d6) d 160.8, 160.1, 154.6, 
153.3, 145.1, 139.1, 128.7, 128.2, 128.0, 127.8, 127.1, 
126.5, 124.1, 113.5, 112.4, 111.4, 101.5, 66.8, 61.6, 48.9, 
18.1; HRMS (ESI) m/z calcd. for C21H19N3O4 [M + H]+: 
378.1454; found: 378.1468.
7-(2-(4-(4-(Hydroxymethyl)phenyl)-1H-1,2,3-triazol-1-yl)
ethoxy)-4-methyl-2H-chromen-2-one (7i)
White solid; yield 89%; mp 181 °C; 1H NMR 
(400 MHz, CDCl3) d 7.86 (s, 1H), 7.76 (d, 2H, J 8.8 Hz), 
7.49 (d, 1H, J 8.8 Hz), 6.97 (d, 2H, J 8.8 Hz), 6.86-6.82 
(m, 2H), 6.15 (s, 1H), 4.84 (t, 2H, J 5.0 Hz), 4.47 (t, 2H, 
J 5.0 Hz), 3.85 (s, 2H), 2.39 (s, 3H); 13C NMR (100 MHz, 
CDCl3) d 161.0, 160.6, 159.7, 155.1, 152.3, 147.9, 127.1, 
125.8, 123.1, 120.0, 114.4, 114.3, 112.6, 112.0, 101.9, 66.8, 
55.3, 49.5, 18.7; HRMS (ESI) m/z calcd. for C21H19N3O4 
[M + H]+: 401.1352; found: 401.1337.
7-(2-(4-(3-Methoxyphenyl)-1H-1,2,3-triazol-1-yl)ethoxy)-4-
methyl-2H-chromen-2-one (7j)
White solid; yield 82%; mp 164-165 °C; 1H NMR 
(300 MHz, DMSO-d6) d 8.68 (s, 1H), 7.67 (d, 1H, J 9.0 Hz), 
7.44-7.41 (m, 2H), 7.35 (t, 1H, J 8.0 Hz), 7.05 (d, 1H, 
J 2.7 Hz), 6.97 (dd, 1H, 9.0, 2.7 Hz), 6.92-6.88 (m, 1H), 
6.21 (d, 1H, J 1.2 Hz), 4.85 (t, 2H, J 5.0 Hz), 4.58 (t, 2H, 
J 5.0 Hz), 3.81 (s, 3H), 2.37 (d, 3H, J 1.2 Hz); 13C NMR 
(75 MHz, DMSO-d6) d 160.83, 160.07, 159.66, 154.62, 
153.36, 146.29, 132.02, 130.05, 126.55, 122.21, 117.50, 
113.53, 112.48, 111.40, 110.39, 101.48, 66.73, 55.11, 
49.04, 18.13; HRMS (ESI) m/z calcd. for C21H19N3O4 
[M + H]+: 378.1454; found: 378.1468.
7-(2-(4-(4-Aminophenyl)-1H-1,2,3-triazol-1-yl)ethoxy)-4-
methyl-2H-chromen-2-one (7k)
White solid; yield 63%; mp 175 °C; 1H NMR (300 MHz, 
DMSO-d6) d 8.35 (s, 1H), 7.67 (d, 1H, J 8.7 Hz), 7.49 (d, 
2H, J 8.7 Hz), 7.05 (d, 1H, J 2.4 Hz), 6.97 (dd, 1H, J 8.7, 
2.4 Hz), 6.60 (d, 2H, J 8.7 Hz), 6.22 (d, 1H, J 1.1 Hz), 5.24 
(s, 2H), 4.79 (t, 2H, J 5.0 Hz), 4.55 (t, 2H, J 5.0 Hz), 2.38 
(d, 1H, J 1.1 Hz); HRMS (ESI) m/z calcd. for C20H18N4O3 
[M + H]+: 363.1457; found: 363.1449.
7-(2-(4-(Pyridin-3-yl)-1H-1,2,3-triazol-1-yl)ethoxy)-4-methyl-
2H-chromen-2-one (7l)
White solid; yield 72%; mp 174 °C; 1H NMR 
(400 MHz, DMSO-d6) d 9.06 (s, 1H), 8.79 (s, 1H), 8.54 (d, 
1H, J 3.2 Hz), 8.23-8.21 (m, 1H), 7.66 (d, 1H, J 8.6 Hz), 
7.50-7.46 (m, 1H), 7.05 (d, 1H, J 2.2 Hz), 6.98 (dd, 1H, 
J 8.6, 2.2 Hz), 6.21 (d, 1H, 0.8 Hz), 4.88 (t, 2H, J 5.0 Hz), 
4.58 (t, 2H, J 5.0 Hz), 2.37 (d, 3H, J 0.8 Hz); 13C NMR 
(100 MHz, DMSO-d6) d 160.8, 160.1, 154.7, 153.4, 148.9, 
146.4, 143.7, 132.4, 126.5, 124.0, 122.7, 113.6, 112.5, 
111.4, 101.6, 66.8, 49.2, 18.1; HRMS (ESI) m/z calcd. for 
C19H16N4O3 [M + H]+: 349.1301; found: 349.1291.
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7-(2-(4-((1H-Benzo[d][1,2,3]triazol-1-yl)methyl)-1H-1,2,3-
triazol-1-yl)ethoxy)-4-methyl-2H-chromen-2-one (7m)
White solid; yield 85%; mp 173-174 °C; 1H NMR 
(300 MHz, DMSO-d6) d 8.35 (s, 1H), 7.95 (d, 1H, J 8.1 Hz), 
7.69 (d, 1H, J 9.0 Hz), 7.36-7.31 (m, 3H), 6.97 (d, 1H, 
J 2.4 Hz), 6.89 (dd, 1H, J 9.0, 2.4 Hz), 6.23 (d, 1H, J 1.1 Hz), 
5.68 (s, 2H), 4.78 (t, 2H, J 5.0 Hz), 4.42 (t, 2H, J 5.0 Hz), 2.40 
(d, 3H, J 1.1 Hz); 13C NMR (75 MHz, DMSO-d6) d 160.7, 
160.1, 154.6, 153.4, 142.5, 139.9, 128.1, 127.5, 127.2, 126.5, 
124.7, 119.5, 113.6, 112.4, 111.4, 108.9, 101.4, 72.7, 66.7, 
48.9, 18.1; HRMS (ESI) m/z calcd. for C20H15N6O4 [M + H]+: 
404.1233; found: 404.1213.
7-(2-(4-(Thiophen-3-yl)-1H-1,2,3-triazol-1-yl)ethoxy)-4-
methyl-2H-chromen-2-one (7n)
White solid; yield 62%; mp 163 °C; 1H NMR 
(400 MHz, DMSO-d6) d 8.52 (s, 1H), 7.85 (dd, 1H, J 3.0, 
1.2 Hz), 7.68-7.63 (m, 2H), 7.52 (dd, 1H, J 4.8, 1.2 Hz), 
7.04 (d, 1H, J 2.8 Hz), 6.97 (dd, 1H, J 8.8, 2.8 Hz), 6.21 (d, 
1H, J 1.2 Hz), 4.84 (t, 2H, J 4.6 Hz), 4.56 (t, 2H, J 4.6 Hz), 
2.37 (d, 3H, J 1.2 Hz); 13C NMR (100 MHz, DMSO-d6) 
d 160.8, 160.1, 154.6, 153.3, 143.0, 132.0, 127.1, 126.5, 
125.8, 121.7, 120.8, 113.5, 112.5, 111.4, 101.5, 66.8, 48.9, 
18.1; HRMS (ESI) m/z calcd. for C18H17N3O3S [M + H]+: 
355.0991; found: 355.1007.
Acetylcholinesterase (AChE) screening assay with 
immobilized capillary enzyme reactor
The screening assay was carried out as previously 
reported.16 Briefly, AChE (E.C. 3.1.1.7) from Electrophorus 
electricus was immobilized onto the internal surface of an 
open tubular capillary (30 × 0.01 cm i.d.) producing AChE-
immobilized capillary enzyme reactor (ICER). Ammonium 
acetate solution (15 mmol L−1, pH 8.0) was used as mobile 
phase, in a flow rate of 0.05 mL min−1. Methanol was used 
to improve ionization. The total analysis time was 20 min. 
Assay was carried out monitoring choline’s precursor ion 
(M)+ 104 m/z and its fragment (C2H3OH)-(M)+ 60 m/z by 
multiple-reaction monitoring (MRM) in which the choline 
precursor ion was used for quantification while MRM ratio 
and the first transition were used for confirmatory purposes.
The 15 synthesized coumarins were then evaluated 
for the inhibition of AChE through the hydrolysis of 
acetycholine (AChE-ICER). To this end, a 1.0 mmol L−1 
methanol stock solution was prepared for each tested 
compound. The 100 μL assay samples were prepared 
with ammonium acetate solution (15.0 mmol L−1, pH 8.0) 
containing 25.0 μL acetycholine aqueous solution 
(1960 μmol L−1) and 20.0 μL of the tested compound 
methanol stock solution. Analyses were carried out by 
aliquots injection of 10.0 μL of each tested coumarins. 
For each tested compound, a negative control (absence of 
acetycholine) and a positive control samples (acetylcholine 
and absence of coumarin) were analyzed. The percent 
inhibition for each compound was calculated using 
equation 1:
 (1)
where Pi stands for the production of choline quantified 
from the hydrolysis of acetylcholine in the presence of the 
tested compounds, and P0 for the production of choline as 
in the positive control experiment.
Molecular modeling studies
The tridimensional structures of compounds were built 
using the on-line version of Corina,17 which ascribes to 3D 
structures pre-defined bond lengths and angles depending 
on the type of bond, type of atom and hybridization state. 
Corina also defines the most probable torsional angles 
according to the nature of the structure (acyclic, small/
medium rings, macro/polycyclic, etc.), being able to 
correctly reproduce a varied number of X-ray structures.18 
Molecular geometries were then refined using the AM1 
semi-empirical force field with the Broyden-Fletcher-
Goldfarb-Shanno (BFGS) algorithm, as implemented in 
the ArgusLab.19 The structure was considered optimized 
when its conformational energy gradient was below 
0.001 kcal mol−1.
Predictions of pharmacological targets were performed 
using PharmMapper.20 PharmMapper identifies potential 
target candidates for a given small molecule by mapping 
the pharmacophore groups in multiple conformations of this 
compound to subsequently search these pharmacophores 
in a large, in-house repertoire of pharmacophore database, 
containing more than 7,000 receptor-based pharmacophore 
models (covering over 1500 drug targets information).21 
Predictions were performed using the general structure 
of 4-methylcoumarins/1,4-substituted 1,2,3-triazole 
conjugates with a methyl substituent at the position 4 of 
the triazole since all compounds have a carbon atom at 
this position. Default setting was used for the maximum 
generated conformations and the compound was screened 
against all pharmacophore models available in the database.
Molecular docking simulations were performed using 
the structure of Torpedo californica AChE complexed 
with an analog of tacrine, 4-amino-5-fluoro-2-methyl-
3-(3-trifluoroacetylbenzylthiomethyl)quinoline (protein 
data bank, PDB code 1HBJ). The structure was checked 
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for missing atoms and amino acid residues using 
PDB_HYDRO22 but none was identified. Protonation states 
for the amino acid residues of acetylcholinesterase were 
calculated at the physiological pH using PROPKA23 and 
set in GOLD 5.324 for the docking simulations. 
GOLD is a widely used docking program in the 
pharmaceutical industry developed by collaboration 
between the University of Sheffield (Sheffield, UK), 
GlaxoSmithKline (London, UK) and the Cambridge 
Crystallographic Data Centre (CCDC).25 GOLD uses 
genetic sampling algorithms, which are inspired by the 
Darwin’s theory of the evolution. The degrees of freedom 
of the ligand are encoded as binary strings called genes 
that make up a chromosome, thus, actually representing the 
pose of the ligand. Therefore, genetic algorithms demand 
that the fittest individuals (poses) are carried on to the next 
generation and random or biased mutations can be made to 
increase genetic (conformational) diversity.26
Simulations were performed inside a 10 Å sphere, for 
which the geometric center (x, y and z coordinates) was 
determined by calculating the centroid of 4-amino-5-fluoro-
2-methyl-3-(3-trifluoroacetylbenzylthiomethyl)quinoline in 
Discovery Studio Visualizer 4.0.27 Default values were set for 
the genetic algorithm parameters and GoldScore was defined 
as the score function. Redocking of the crystallographic 
ligand into the binding site of acetylcholinesterase yielded a 
heavy atom root mean square deviation (RMSD) of 1.1591 Å. 
The best pose of the compounds was selected for visual 
inspection and analyses of protein-ligand interactions in 
Discovery Studio Visualizer.
Results and Discussion
The synthetic route for the 4-methylcoumarins/1,4-
substituted 1,2,3-triazole is outlined in Scheme 1:
7 - H y d r o x y - 4 - m e t h y l c h r o m e n - 2 - o n e  ( 3 , 
4-methylumbelliferone) was synthesized using the 
Pechmann reaction,13 where a phenol 1, under acid 
catalysis, undergoes electrophilic aromatic substitution 
with a β-ketoester 2 to give an intermediate that cyclizes by 
a transesterification reaction to produce the 2H-chromen-2-
one nucleus.8 Alkylation of the phenolic group of 3 using 
1,2-dibromoethane and potassium carbonate in acetonitrile 
yielded 4, which was then converted into the azide 
derivative 5 via nucleophilic substitution by using sodium 
azide in acetone.14 Synthesis of 4-methylcoumarins/1,4-
substituted 1,2,3-triazole conjugates was, then, achieved 
by coupling the azido-coumarin 5 with a set of structurally 
diverse terminal alkynes by using the copper(I)-catalyzed 
alkyne-azide cycloaddition reaction,15 in good yields and 
with complete regioselectivity.
To predict the most feasible pharmacological 
target for these compounds, we performed a search 
using PharmMapper, which maps the pharmacophore 
groups in small molecules to search for complementary 
pharmacophores in a drug target database.21 Results 
for the top five predicted targets are shown in Table 1, 
illustrating that the acetylcholinesterase enzyme displayed 
the best fit score regarding the complementary between the 
pharmacophore groups of the ligand with the corresponding 
functionalities in the macromolecular target.
This theoretical prediction is supported by the 
fact that several coumarins are known to inhibit the 
acetylcholinesterase enzyme.28 Ensaculin (Figure 2, 8) is 
probably the most prominent of these compounds, being 
identified as a lead compound when a series of synthetically 
modified coumarins were screened. This coumarin 
demonstrated to have facilitatory effects on learning and 
memory in rats and to inhibit rat brain acetylcholinesterase 
activity in vitro with an IC50 of 0.36 μmol L-1, without 
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Scheme 1. Synthesis of 4-methylcoumarins/1,4-substituted 1,2,3-triazole conjugates. Reagents, conditions and yields: (i) H2SO4, r.t., overnight (67%); 
(ii) BrCH2CH2Br, K2CO3, CH3CN, reflux, 6 h (52%); (iii) NaN3, (CH3)2CO, reflux, 4 h (89%); and (iv) CuSO4, sodium ascorbate, dimethylformamide, 
microwave 70 °C (18 W), 20-30 min (59-91%).
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affecting the activity of butyrylcholinesterase.29 Although 
few patients presented postural hypotension and dizziness 
after receiving ensaculin in phase I clinical trials, this drug 
candidate was further discontinued in phase III due to 
potential side effects.30
The synthesized conjugates were assayed as 
acetylcholinesterase inhibitors (Table 2). The most 
prominent compound in this series was the conjugate 7g, 
which inhibited almost 60% of the enzyme activity at 
200 μmol L–1. Compounds with hydrogen bond donors/
acceptor groups close to the triazole ring, e.g., compounds 
7a, 7b, 7m, and 7n, also displayed intermediate inhibitory 
activities against AChE.
By using molecular docking simulations, we compared 
the putative binding mode of the most active compound of 
this series, 7g, with the crystallographic pose of the ligand 
suggested by the pharmacophore search in PharmMapper, 
the tacrine analog (Figure 3a), 4-amino-5-fluoro-2-methyl-
3-(3-trifluoroacetylbenzylthiomethyl)quinoline (10, PDB 
code 1HBJ), and with donepezil (11, PDB code 1EVE), 
an acetylcholinesterase inhibitor that is clinically used to 
treat Alzheimer’s disease.
The active site of acetylcholinesterase is composed 
by two subsets. The first is the catalytic subsite, which 
comprises residues that are essential for the hydrolase 
activity of the enzymes: Ser200, Glu327 and His440 
(known as the catalytic triad). The second, the anionic 
subsite (Trp84, Tyr130, Tyr330 and Phe331), binds the 
quaternary trimethylammonium choline moiety of the 
substrate, mainly via π-cation interactions. The active site 
lies deep within the molecule at the base of a narrow 20 Å 
deep gorge, lined predominantly with aromatic residues. 
Located at the opening of the gorge (approximately 14 Å 
from the main active site), there is a second binding site, 
the peripheral anionic site, composed by the residues Tyr70, 
Asp72, Tyr121, Trp279 and Tyr334. The residues Trp84 in 
the anionic subsite and Trp279 in the peripheral anionic site 
have been the basis for the design of the newest generation 
of acetylcholinesterase inhibitors, e.g., donepezil.32-34 
Compound 10 performs interactions only with 
residues from the catalytic and the anionic subsite of 
acetylcholinesterase, which compose its active site.35 
This is a common feature for most of the clinically useful 
inhibitors of acetylcholinesterase, i.e., tacrine, rivastigmine, 
and galantamine, which prevent the binding of the substrate 
or its hydrolysis by occupying the active site with a high 
affinity. Donepezil, however, is the only drug that interacts 
with the peripheral anionic site, since its indadone moiety 
interacts with Trp279 whilst the benzylpiperidine fragment 
interacts in the catalytic site with the Trp84.32
In spite of the differences between tacrine and 
donepezil concerning their binding mode to the active site 
of acetylcholinesterase, there is no evidence that any of 
these drugs is superior in terms of clinical efficacy. In vitro, 
donepezil is approximately 40 times more potent than 
tacrine as an inhibitor of acetylcholinesterase; previously, 
we determined the IC50 of tacrine via AChE-ICER as 
0.386 ± 0.044 μmol L–1,15 while the IC50 of donepezil, 
calculated using immobilized AChE stationary phase, was 
0.0092 ± 0.0015 μmol L–1.36 Clinically, donepezil has been 
found to be better tolerated, with less gastrointestinal side 
effects than rivastigmine or galantamine, while the clinical 
use of tacrine has been abandoned in many countries 
because of the high incidence of side effects, including 
hepatotoxicity.37 The other putative advantage of drugs that 
block the access of the substrate to the peripheral anionic 
concerns to the secondary noncholinergic functions of the 
enzyme (adhesion, differentiation and deposition of beta-
amyloid in Alzheimer’s disease), which has been ascribed 
precisely to the peripheral anionic site.32,38
Table 1. Top five predicted targets for a 4-methylcoumarins/1,4-substituted 1,2,3-triazole conjugate using PharmMapper
Target PDB Code Pharmacophore featurea Fit scoreb
Acetylcholinesterase 1HBJ 9 4.755
PDK-1 2PE1 7 4.542
trans-Sialidase from Trypanosoma cruzi 1S0J 12 4.519
Aldose reductase 2FZ8 6 4.458
aTotal number of pharmacophore features that are complementary to the pharmacophore models of the target proteins; bpairwise alignment between the 
two pharmacophoric models. PDB: protein data bank; PDK-1: phosphoinositide-dependent kinase-1.
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Figure 2. Chemical structure of ensaculin (8, 7-methoxy-6-{3-[4-
(2-methoxyphenyl)-1-piperazinyl] propoxy}-3,4-dimethyl-2H-1-
benzopyran-2-one).
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Comparing the binding modes of 7g and donepezil, 
there is an almost perfect superposition between the 
phenyl ring of the 2H-chromen-2-one core with the 
corresponding one from the indadone moiety from 
donepezil (Figure 3b), both performing π-π interactions 
with Trp279 (Figures 3c and 3d), although this ring seems 
to be properly orientated to interact with Tyr121 only 
in donepezil 11. It was observed that the nitrogen in the 
piperidine from 11 is protonated at the physiological pH, 
being able to establish a cation-π interaction with Phe330.39
A similar interaction is not expected to be observed in 
7g because 1,2,3-triazoles are poorly basic in nature and, 
consequently, their nitrogen atoms remain non-protonated 
under the physiological pH.40 According to the docking 
simulations, the triazole moiety 7g only interacts with 
one water molecule via hydrogen bonding (Figure 3d), 
and, therefore, makes no direct interaction with amino 
acid residues of AChE. Finally, while the terminal phenyl 
group of donepezil is directed toward Trp84 to establish π-π 
interactions, in 7g the corresponding phenyl interacts with 
Phe330. Compound 7g and donepezil putatively occupy 
both the anionic subsite and the peripheral anionic site, the 
overall interactions is consistent with the fact that 7g is a 
weaker inhibitor of acetylcholinesterase than donepezil.
Conclusions
Although the most prominent compound in this series 
inhibited only almost 60% of the acetylcholinesterase 
activity at 200 μmol L−1, docking simulations suggest 
that this compound binds similarly to donepezil and, 
consequently, this compound can putatively block the 
secondary noncholinergic functions of the enzyme, 
which include adhesion, differentiation and deposition 
of beta-amyloid in Alzheimer’s disease. Therefore, we 
believe that coumarin 7g may serve as a good starting point 
for further optimization of this series, but this will also 
require more in-deep analyses, concerning the mechanism 
of action of these compounds. It is now recognized that 
the pathogenesis of Alzheimer’s disease can lead to the 
generation of toxic processes involving dysregulation of 
amyloid precursor protein metabolism, inflammation, 
oxidative stress, apoptosis, proteosome inhibition, 
mitochondrial dysfunction, imbalances in antioxidant 
production and glutamate excitotoxicity, amongst others.41 
Therefore, anti-inflammatory and antioxidant actions, 
which are typically observed for natural coumarins,8 
can also be explored in 4-methylcoumarins/1,2,3-
triazoles conjugates to yield multitarget ligands in 
the search of new compounds for the treatment of 
Alzheimer’s disease.
Table 2.  Inhibition percentages of 4-methylcoumarins/1,4-
substituted 1,2,3-triazole conjugates against Electrophorus electricus 
acetylcholinesterase (AChE) immobilized onto a fused silica capillary 
enzyme reactor (eelAChE-ICER) in a liquid chromatography-tandem 
ion-trap mass spectrometer (LC-IT-MS/MS). Full structures of 
4-methylumbelliferone and tacrine are shown in this table. The general 
structure for the corresponding R groups in the 4-methylcoumarins/1,4-
substituted 1,2,3-triazole conjugates is depicted in Scheme 1, structure 7
Compound R Inhibition at 200 μmol L−1 / %
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7b
H3C
OH
 
37.28
7c OH
 
27.79
7d
 
4.42
7e
F3C
 
29.73
7f
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7g
 
59.52
7h
HO
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−3.90
7j
O
CH3
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7k
NH2
 
20.16
7l N
 
16.28
7m N
N N
 
35.50
7n S
 
30.45
3
OO OH
 
13.13
9a
N
NH2
 
99.30
aThe IC50 of tacrine (0.386 ± 0.044 μmol L−1) and their inhibition 
percentage at 200 μmol L–1 were previously determined by our research 
group as reported.16,31
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